Supriya Lifescience Limited — Investor Meet, 17-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Supriya Lifescience posted Q3 FY26 revenue of INR206 Cr (+11% YoY), EBITDA of INR72 Cr (35% margin), and PAT of INR50 Cr. Nine-month revenue was INR551 Cr. Management is confident in ~20% FY26 revenue growth and targets INR1,000 Cr by FY27. Drivers include new product launches (cardiovascular, ADHD), Ambernath CDMO facility set for Q4 capitalization (expecting 2.5x capex revenue), and robust backward integration (74% of Q3 revenue). Strategic focus on regulated markets positions for sustained growth.